Phase III data shows Onbrez better for COPD than salmeterol

Novartis has announced that its Phase III INSIST study shows that its once-daily Onbrez Breezhaler indacaterol DPI produces better bronchodilation in COPD patients than does twice-daily salmeterol. Onbrez also reduced the need for rescue medication, according to the data presented. The FDA has requested additional clinical data from Novartis for consideration of US regulatory approval, and the company says that it plans to file that data in November. Read the company’s press release.